Previous 10 | Next 10 |
TransMedics Group press release (NASDAQ:TMDX): Q4 GAAP EPS of -$0.46 misses by $0.03. Revenue of $9.7M (+27.3% Y/Y) beats by $2.17M. 2022 Outlook: TransMedics expects net revenue for the full-year 2022 to be in the range of $49 million to $55 million, which represents 62% to 82% growth compar...
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire ANDOVER, Mass. , Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy f...
AAN, ACA, OTCPK:ACLLF, AEM, AEVA, AGI, AHT, ALLO, ALR, AMED, ANSS, ARNA, AZUL, BAND, BBDC, BBWI, BCSF, BHP, BIRD, BKNG, BMA, BMRN, CCRN, CDEV, CHDN, CHK, CLOV, CMLS, CPE, CSV, CTRA, CW, DHC, DK, DKL, EBAY, EFC, OTCPK:EIFZF, EVH, EXR, FBRT, FIVN, FIX, FLGT, FLS, FNF, FRG, FTI, FUBO, GBT, GH, G...
TransMedics to Present at the Cowen 42nd Annual Healthcare Conference PR Newswire ANDOVER, Mass. , Feb. 22, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for...
TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 PR Newswire ANDOVER, Mass. , Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming...
TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery PR Newswire ANDOVER, Mass. , Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ ...
TransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire ANDOVER, Mass. , Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transpla...
TransMedics Group, Inc. (TMDX) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Brian Johnston - VP, IR Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Bill Plovanic - Canaccord Allen Gong - JPMorgan Calvin Chu - Morga...
TransMedics Group (NASDAQ:TMDX): Q3 GAAP EPS of -$0.47 misses by $0.15. Revenue of $5.37M (-24.4% Y/Y) misses by $0.98M. Press Release Cash, cash equivalents and marketable securities were $102.9M as of September 30, 2021. For further details see: TransMedics Group EPS misses by $0.15, ...
TransMedics Reports Third Quarter 2021 Financial Results PR Newswire ANDOVER, Mass. , Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...